ArticleDiscover oncology2025
Database analysis reveals endophilin A expression as a marker of metastasis and prognosis in breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndophilin A, a family of Bin-Amphoterisin-Rvs (BAR) domain-conserved proteins, is found in several tissues and is associated with disease pathogenesis. In patients with breast cancer, endophilin A expression pertains to boosted tumour cell endocytosis, migration, and invadopodia formation, potentially linked to a poor prognosis.
methodsThis study aimed to determine the expression of endophilin A isoforms (SH3GL1, SH3GL2, and SH3GL3) in breast cancer using databases like UALCAN, GEPIA2, TIMER 2.0, geneMANIA, Enrichr, Km Plotter, and GENT2.
resultsWe report the elevated expression of SH3GL1 in TNBC and HER2 subtypes of breast carcinoma, and that positively correlated with advancing stage as well as lymph node metastasis, compared to SH3GL2 and SH3GL3. Additionally, the study demonstrates that in contrast to SH3GL1 and SH3GL3, elevated SH3GL2 transcript levels were positively associated with improved Overall Survival (OS), Relapse Free Survival (RFS), and Distance Metastasis Free Survival (DMFS compared to low expression levels among the breast cancer patients. Further, we also show the associated immune filtration with each endophilin isoform and link the expression of endophilin A isoform with p53 expression.
conclusionsBased on our findings, it is possible to conclude that endophilin A isoforms-long recognised for orchestrating endocytosis and metastatic behaviour-may represent a critical molecular fulcrum in breast cancer progression. In particular, elevated expression of endophilin A2 (SH3GL1) and SH3GL2 strongly correlates with poor prognosis and node-positive breast cancer, highlighting their potential as promising biomarkers for breast cancer assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.